New report confirms calpainopathy is most common type of LGMD

A paper recently published by Madhuri Hegde, Emory University, and colleagues analyzed the outcomes of genetically sequencing a large group of patients with limb girdle weakness in the United States.

This study is unique in that it included a very large cohort of patients – 4656 – who were enrolled in the Muscular Dystrophy Association (MDA) and Jain Foundation LGMD molecular diagnostic testing programs from June 2015 to June 2017. Patients with suspected LGMD provided blood samples, which were subjected to Next Generation Sequencing of a targeted gene panel containing genes that cause LGMD, as well as genes that cause clinically similar muscular dystrophies.

Twenty seven percent of patients received a genetic diagnosis, with the most common causative LGMD genes being:

  • CAPN3/LGMD2A&1I (17%)
  • DYSF/LGMD2B (16%)
  • FKRP/LGMD2I (9%)
  • ANO5/LGMD2L (7%)

Other interesting findings include:

  • Report of a new CAPN3 mutation, c.598_612del15, that appears to cause autosomal dominant calpainopathy (LGMD1I). Further studies are required to confirm the dominant inheritance of this mutation.
  • 31 individuals had pathogenic mutations in more than one LGMD gene, suggesting multigenic inheritance (LGMD as a result of mutations in more than gene)

The full text of the study can be found here.

Recent Posts

  • New Research Grant Aims to Improve Understanding of Dominant Calpainopathy

    C3 is pleased to share that a research grant has been awarded to Drs. Ana Töpf, Jordi Diaz-Manera, and Volker Straub at the John Walton Muscular Dystrophy Research Centre at Newcastle University. This project, titled “Understanding the variable expression of dominant calpainopathies,” explores the molecular basis for LGMDD4, also known as dominant calpainopathy. The Challenges... Read More
  • Dr. Melissa Spencer provides update on development of an LGMD2A/R1 gene therapy

    Melissa Spencer, PhD, Chair of the C3 Scientific Advisory Board and Professor of Neurology at UCLA, recently presented during a webinar hosted by the Muscular Dystrophy Association (MDA). The presentation, aimed at educating the public, gave an excellent background about genes, mutations, and adeno-associated vector (AAV)-based gene therapies. She highlights some of the latest advances... Read More